Karg MV - Search Results

1

Predicting blood pressure response to renal denervation based on a new approach.

Bytyqi V, Kannenkeril D, Striepe K, Bosch A, Karg MV, Schmid A, Schiffer M, Uder M, Schmieder RE. Bytyqi V, et al. Among authors: karg mv. J Hypertens. 2024 Oct 30. doi: 10.1097/HJH.0000000000003918. Online ahead of print. J Hypertens. 2024. PMID: 39526682

2

Application of a central iliac arteriovenous coupler device in severe treatment-resistant hypertension: a 3.5-year follow-up.

Jung S, Ott C, Karg MV, Bosch A, Schmid M, Schlundt C, Achenbach S, Schmieder RE. Jung S, et al. Among authors: karg mv. J Hypertens. 2018 Dec;36(12):2471-2477. doi: 10.1097/HJH.0000000000001873. J Hypertens. 2018. PMID: 30113527

3

Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation.

Bosch A, Schmid A, Ott C, Kannenkeril D, Karg MV, Ditting T, Veelken R, Uder M, Schmieder RE. Bosch A, et al. Among authors: karg mv. Am J Hypertens. 2020 Feb 22;33(2):182-189. doi: 10.1093/ajh/hpz155. Am J Hypertens. 2020. PMID: 31555795

4

Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension.

Schneider A, Schwab J, Karg MV, Kalizki T, Reinold A, Schneider MP, Schmieder RE, Schmidt BM. Schneider A, et al. Among authors: karg mv. J Hypertens. 2017 May;35(5):1086-1092. doi: 10.1097/HJH.0000000000001264. J Hypertens. 2017. PMID: 28118280 Clinical Trial.

5

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.

Karg MV, Bosch A, Kannenkeril D, Striepe K, Ott C, Schneider MP, Boemke-Zelch F, Linz P, Nagel AM, Titze J, Uder M, Schmieder RE. Karg MV, et al. Cardiovasc Diabetol. 2018 Jan 4;17(1):5. doi: 10.1186/s12933-017-0654-z. Cardiovasc Diabetol. 2018. PMID: 29301520 Free PMC article. Clinical Trial.

6

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.

Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D, Dienemann T, Schmieder RE. Bosch A, et al. Among authors: karg mv. Cardiovasc Diabetol. 2019 Mar 29;18(1):44. doi: 10.1186/s12933-019-0839-8. Cardiovasc Diabetol. 2019. PMID: 30922297 Free PMC article. Clinical Trial.

7

Tissue sodium content in patients with type 2 diabetes mellitus.

Kannenkeril D, Karg MV, Bosch A, Ott C, Linz P, Nagel AM, Uder M, Schmieder RE. Kannenkeril D, et al. Among authors: karg mv. J Diabetes Complications. 2019 Jul;33(7):485-489. doi: 10.1016/j.jdiacomp.2019.04.006. Epub 2019 Apr 16. J Diabetes Complications. 2019. PMID: 31101486

8

Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.

Jung S, Bosch A, Kannenkeril D, Karg MV, Striepe K, Bramlage P, Ott C, Schmieder RE. Jung S, et al. Among authors: karg mv. Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):364-371. doi: 10.1093/ehjcvp/pvz078. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31816038 Clinical Trial.

9

The influence of aircraft noise exposure on the systemic and renal haemodynamics.

Bosch A, Kannenkeril D, Jung S, Striepe K, Karg MV, Ott C, Schmieder RE. Bosch A, et al. Among authors: karg mv. Eur J Prev Cardiol. 2022 Feb 19;29(1):116-124. doi: 10.1093/eurjpc/zwaa036. Eur J Prev Cardiol. 2022. PMID: 33623977

10

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.

Ott C, Jumar A, Striepe K, Friedrich S, Karg MV, Bramlage P, Schmieder RE. Ott C, et al. Among authors: karg mv. Cardiovasc Diabetol. 2017 Feb 23;16(1):26. doi: 10.1186/s12933-017-0510-1. Cardiovasc Diabetol. 2017. PMID: 28231831 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters